Clinical Manifestations of Neuro-COVID Syndrome

Firooz Salehpour[1], Mohammad Shimia[1], Ali Riazi[2] and Ata Mahdkhah[1]*

[1]*Department of Neurosurgery, Tabriz University of Medical Sciences, Tabriz, Iran*
[2]*Department of Neurosurgery, Isfahan University of Medical Sciences, Isfahan, Iran*

*Corresponding Author: Ata Mahdkhah, Department of Neurosurgery, Tabriz University of Medical Sciences, Tabriz, Iran.

Clinical symptoms and signs of CNS (Central Nervous System) and PNS (Peripheral Nervous System) involvement can be seen in up to 25% of SARS-CoV-2 (Severe acute respiratory syndrome coronavirus-2) infected patients. Some researchers propose the term "Neuro-COVID syndrome" for presentations with pure CNS and PNS presentations at onset. We want to have a mini-review of neurological manifestations of coronavirus disease in this editorial.

Based on literature, there are different symptoms and signs related to SARS-CoV-2 [1-11]:

1. Dizziness which is not a specific symptom. It can be seen in most of the cases.

2. Headache with different pathophysiology according to phase of COVID-19 illness.

3. Altered mental state which can be detected in up to 9% of hospitalized COVID-19 patients, especially severe cases.

4. Meningitis with different manifestations including delirium (71%), aphasia (53%), headache (34%), seizures/status epilepticus (34%), focal neurological deficits (18%), and myoclonus (9%) with a single patient having parkinsonian syndrome (3%).

5. Encephalitis which is reported with more fulminant course.

6. Ischemic stroke due to pro-coagulant state, which may result from either blood flow stasis, particularly in critically ill patients or hypercoagulability and direct endothelial damage via ACE-2 (Angiotensin-converting enzyme 2) receptors.

7. Hemorrhagic stroke due to cerebral autoregulation dysfunction.

8. Venous sinus thrombosis with pathophysiology like stroke.

9. Seizure due to direct invasion of SARS-CoV-2 or results of hypoxia, metabolic and electrolyte imbalances.

10. Subarachnoid hemorrhage with an unknown mechanism.

11. Neuroimmunological disorders may be due to demyelination and a delayed immune response.

12. Movement disorders as a result of COVID-19-associated immune activation in the olfactory system leading to alpha-synuclein misfolding and development of Parkinsonian features.

13. Smell impairment reported in 5 - 90% COVID-19 cases, with females outnumbering males.

14. Taste impairment more commonly reported in European cases as compared to Asian.

15. Guillain-Barre syndrome with postinfectious immune-mediated pathology.

16. Myasthenia gravis which can be seen in some reports. The probable molecular mimicry between the SARS-CoV-2 proteins and acetylcholine receptor might have activated the immune response.

17. Myositis in critically ill patients.

18. Rhabdomyolysis can be seen in hospitalized cases.

19. Myopathy which may be detected in ill patients.

20. Neuropathy which is usually seen in critical phase of disease.

21. Hydrocephalus with an unknown pathophysiology.

Useful investigations for these manifestations are:

1. Neuroimaging including brain computed tomography (CT), positron emission tomography (PET) and brain magnetic resonance imaging (MRI),

2. Cerebrospinal Fluid (CSF) analysis,

3. Electroencephalography (EEG),

4. Electrophysiological studies.

The most important conclusion of this editorial is that the virus may present with an extensive range of CNS and PNS manifestations.

Bibliography

1. Song F., *et al*. "Emerging 2019 novel coronavirus (2019-nCoV) pneumonia". *Radiology* 295.1 (2020): 210-217.

2. Kim ES., *et al*. "Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 Infection: a preliminary report of the first 28 patients from the Korean Cohort Study on COVID-19". *Journal of Korean Medical Science* 35.13 (2020): e142.

3. Pan F., *et al*. "Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia". *Radiology* 295.3 (2020): 715-721.

4. Du R-H., *et al*. "Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study". *European Respiratory Journal* 55.5 (2020): 1-8.

5. Centers for Disease Control and Prevention. Evaluating and testing persons for coronavirus disease 2019 (COVID-19) (2020).

6. Lei Z., *et al*. "A cross-sectional comparison of epidemiological and clinical features of patients with coronavirus disease (COVID-19) in Wuhan and outside Wuhan, China". *Travel Medicine and Infectious Disease* 35 (2020): 1-6.

7. Liu Y., *et al.* "Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury". *Science China Life Sciences* 630.3 (2020): 364-374.

8. Murad MH., *et al.* "Methodological quality and synthesis of case series and case reports". *BMJ Evidence-Based Medicine* 23.2 (2018): 60-63.

9. Shen L., *et al.* "Clinical and laboratory-derived parameters of 119 hospitalized patients with coronavirus disease 2019 in Xiangyang, Hubei Province, China". *Journal of Infection* (2020).

10. Shi H., *et al.* "Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study". *The Lancet Infectious Diseases* 20.4 (2020): 425-434.

11. Lu R., *et al.* "Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding". *Lancet* 395.10224 (2020): 565-574.

Volume 13 Issue 9 September 2021